-
Sector Analysis
NewCell and Gene Therapies in Hemophilia A and B – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies (CGT) in Hemophilia A and B Market Report Overview The hemophilia A and B CGT market reached $12 million in 2023 with massive expansions across therapeutic areas. The CGT in Hemophilia A and B market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in Hemophilia A & B including launch date projections, key clinical trial analysis, analyst consensus forecasts, likelihood of approval analysis, and commentary on current and...
-
Product Insights
Hemophilia A (Factor VIII Deficiency) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
A total of 721 Hemophilia A (Factor VIII Deficiency) clinical trials were conducted as of February 2024. The Hemophilia A clinical trial report provides a comprehensive understanding of the Hemophilia A (Factor VIII Deficiency) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Product Insights
Thalassemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Thalassemia - Drugs In Development, 2023’, provides an overview of the Thalassemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Beta Thalassaemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Beta Thalassaemia - Drugs In Development, 2023’, provides an overview of the Beta Thalassaemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Beta Thalassaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drugs In Development, 2023
Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drugs In Development, 2023’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukocyte Disorders (White Blood Cell Disorders) - Drugs In Development, 2023’, provides an overview of the Leukocyte Disorders (White Blood Cell Disorders) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukocyte Disorders (White Blood Cell Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Anemia in Chronic Kidney Disease (Renal Anemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Anemia in Chronic Kidney Disease (Renal Anemia) - Drugs In Development, 2023’, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Paroxysmal Nocturnal Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Paroxysmal Nocturnal Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hemophilia B (Factor IX Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia B (Factor IX Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia B (Factor IX Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia B (Factor IX Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...